NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Alaunos Therapeutics, Inc. TCRT
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5,000
▼ 50.0% vs FY2024
EPS · FY25
$-2.20
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-198.1%
Net margin · FY25
-83520.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5,000.00
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 83520 cents on every revenue dollar this year.
Per share
USD -2.20
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-198.1%
Return on equity, FY2025
ROE
Operating margin-84500.0%
Net margin-83520.0%
Return on assets-146.0%
Each USD of equity lost 198 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−88.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years+63.3%
Change, 10 years+212.3%
The share count grew 63% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.0M
total assets, end of FY2025
Total assetsUSD 3.0M
EquityUSD 2.2M
CashUSD 1.4M
Current ratio2.45×
Equity funds 73% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
·
·
·
0.0
0.0
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.1
·
·
·
·
·
·
·
·
Income tax $B
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.20
−2.92
−21.97
−2.61
−0.37
−0.38
−0.70
0.96
−0.53
−1.32
−0.96
−0.31
−0.66
−1.22
−0.97
−0.71
−0.33
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−198.1
−111.8
−20.9
−78.1
−86.5
−73.0
−130.5
·
·
−3282.0
−198.1
−76.4
−116.7
−160.2
−124.9
−111.4
−43.9
−136.0
−87.6
Shares out B
0.00
0.00
0.00
0.02
0.22
0.21
0.18
0.16
0.14
0.13
0.13
0.10
0.10
0.08
0.07
0.05
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed